Navigation Links
Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Date:4/2/2008

l partner on clinical development and funding are pending.

The program for measles and RSV will be tested up to and through clinical Phase I, where it is expected that proof of concept will be obtained.

As for HIV multiantigen, Phase I/II clinical studies will be completed, and partnering negotiations will be initiated as and when the project progresses.

Building market demand for IMVAMUNE(R)

As part of the process of taking the Bavarian Nordic organization to new and professional levels, a new commercial organization was established in 2007 in order to strengthen the Company's commercial activities and build market demand for IMVAMUNE(R) and future vaccines, including HIV and cancer vaccines.

Changes in management

During the past year the Executive Management of Bavarian Nordic has been strengthened with new CEO and an Executive Vice President Commercial Affairs. To implement the new strategic initiatives, the Executive Management will be further strengthened with two new people and the appointment of a new member.

Rene Djurup, Executive Vice President Technical Operations, has decided to resign from his position as of 31 May 2008 in order to dedicate himself to private business activities. The build-up of the Company's production facility - the world's first MVA production plant, was a fantastic achievement headed by Rene, and the Company wishes to thank him for his great effort and contribution to the industrial development of Bavarian Nordic.

Anders Gram (48) has been appointed as new Executive Vice President Technical Operations. Anders holds an M.Sc. degree in chemical engineering and a Ph.D. in industrial biochemistry. He currently holds the position as Managing Director and Vice President, Biopharma Operations in Novozymes. Previously he worked in various management positions within product supply in the enzyme business area at Novo Nordisk. He will take up position on 1 June 2008 at the latest.


'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Vista Partners Updates Coverage; Maintains $3.20 Target Price
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
5. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
6. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
7. ImaRx to Report Corporate Updates and 4Q07 Financial Results
8. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
9. InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
10. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:7/31/2014)... City, CA (PRWEB) July 31, 2014 ... as consumers, are increasingly searching for food alternatives ... and nutritional benefits. The food ingredient market has ... budding players such as Vital Force Technology (VFT). ... with more than 4,000 energetic patterns, all tested ...
(Date:7/31/2014)... British mathematician (1912-1954), is famous for a number of ... In 1936 he published a paper, which laid the ... of a computer algorithm. He next played a pivotal ... which cracked the German military codes, enabling the Allies ... in the late 1940,s he turned his attention to ...
(Date:7/31/2014)... New York , July 31, 2014 ... by Transparency Market Research "Quantum Dots Market - Global ... - 2023," the market was valued at USD 88.5 ... 8,246.8 million by 2023, growing at a CAGR of ... full Quantum Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html ...
Breaking Biology Technology:Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4
... 4 Immtech Pharmaceuticals,Inc. (AMEX: IMM ) ... exclusive,license to BioAlliance Pharma SA (Euronext Paris - ... maleate (pafuramidine), in,Europe for the treatment of pneumocystis ... of Human African trypanosomiasis, also known as,African sleeping ...
... Israel, December 4 Healthcare,Technologies Ltd. (NASDAQ: ... its unaffiliated and voting shareholders (approximately 90%),voted in ... the meeting, the shareholders were asked to approve ... Inc, Mac,Bioventures Inc. and Gamida for Life B.V. ...
... Biotest Pharmaceuticals,Corporation, a leading developer of ... management team as part of the formal,completion ... (Nasdaq:,NABI) and the creation of Biotest Pharmaceuticals. ... Corporation Completes Acquisition,of Nabi Biologics Business Unit," ...
Cached Biology Technology:Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 2Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 3Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 4Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction 2Biotest Pharmaceuticals Corporation Announces Management Team 2Biotest Pharmaceuticals Corporation Announces Management Team 3
(Date:7/31/2014)... Bureau, Latinos are the largest minority group in the ... one-third of Latinos are obese and are 1.2 times ... , NYU College of Nursing student researcher Lauren ... the factors that contribute to this problem by compiling ... food patterns in Latina women recently published in ...
(Date:7/31/2014)... (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity ... (HPV) vaccine Cervarix. Women vaccinated with the ... than nine years, and vaccine efficacy (VE) ... the longest follow-up report for a licensed ... the full paper. , HPV and ...
(Date:7/31/2014)... An international team of scientists from Spain, France, ... rove beetle that is the oldest definitive member ... found in amber. The discovery and description were ... phase-contrast X-ray synchrotron imaging technique, which allows the ... amber. The new species is described in the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... The second annual Epigenetic Control and Cellular Plasticity ... remodeling contribute to various processes that lead to cellular ... 12-13, at the At the Beckman Center of the ... INFORMATION: Media planning to attend should ...
... concern over possible large and rapid changes in the physical ... oceans. Some of these changes could occur within a ... and ecosystems to adapt. A new report from the ... stating that even steady, gradual change in the physical climate ...
... the Hebrew university of Jerusalem and the startup company ... diseases. The researchers found that TyrNovo,s novel and unique ... in order to protect the brain from neurodegenerative diseases, ... step towards the development of future drugs for the ...
Cached Biology News:Top scientists to present at Epigenetic Control and Cellular Plasticity symposium 2New report calls for attention to abrupt impacts from climate change 2New report calls for attention to abrupt impacts from climate change 3New compound for slowing the aging process can lead to novel treatments for brain diseases 2New compound for slowing the aging process can lead to novel treatments for brain diseases 3
... Thermo has established an expertise in ... both for solid support synthesis and synthesis ... controlled by Mass Spectrometry and analytical HPLC ... provide products that meet the highest quality ...
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... dispensers save space and organize ... and other garb. They are ... for small parts used in ... acrylic. Many other sizes and ...
Biology Products: